Priscilla Y. Hsue

• University of California Los Angeles

• University of California, San Francisco

Sources: reporter.nih.gov

• National Heart, Lung, and Blood Institute

  R01, Evaluation of Novel Clonal Hematopoiesis Of InDEterminate Potential, Mosaic Chromosomal Alterations and CardioVascular Disease in HIV Infection (ENCODE CVD in HIV), R01HL170600, 2023–2027, 18 Sept 2026

• National Heart, Lung, and Blood Institute

  R01, Reducing Arterial Inflammation using Eplerenone and Statins to Augment Cardiovascular Health in HIV, R01HL189470, 2026–2031, 10 Sept 2026

• National Heart, Lung, and Blood Institute

  R01, Cholesterol and inflammation Lowering via BEmpedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial), R01HL164337, 2022–2027, 7 Sept 2026

• National Heart, Lung, and Blood Institute

  R01, Evaluation of Glucagon-Like Peptide-1 Receptor Agonist on Pathophysiology of Inflammation and Atherosclerosis in Persons Living With HIV: A Multicenter Randomized Placebo-Controlled Tri, R01HL184987, 2026–2031, 7 Jul 2026

• National Institute on Aging

  R01, REVERSE-Long COVID: A Multicenter Randomized, Placebo-Controlled Clinical Trial of Immunomodulation (with Baricitinib) for Long COVID Related ADRD, R01AG085873, 2024–2028, 6 Feb 2026

• National Institute of Allergy and Infectious Diseases

  K24, Role of Hematopoietic System and Proteomics in HIV-Associated CardiovascularDisease, K24AI112393, 2024–2026, 19 Aug 2024

Sources: reporter.nih.gov